Kymera Therapeutics
OverviewSuggest Edit
Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.
| Type | Private | |
| Founded | 2017 | |
| HQ | Watertown, MA, US | Map |
| Website | kymeratx.com |
Recent NewsAll News
- Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
- Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
- Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Key People/Management at Kymera Therapeutics
Nello Mainolfi
Founder, President, Chief Executive Officer & Director
Jared Gollob
Chief Medical Officer
Bruce Jacobs
Chief Financial Officer
Richard Chesworth
Chief Scientific Officer
Ashwin Gollerkeri
Senior Vice President, Head of Development, Director
Brian Albarran
Vice President, Strategy and Operations
Kymera Therapeutics Office Locations
Kymera Therapeutics has an office in Watertown
Watertown, MA, US (HQ)
200 Arsenal Yards Blvd #230
Kymera Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Kymera Therapeutics total Funding | $197 m |
Kymera Therapeutics latest funding size | $102 m |
Time since last funding | a year ago |
Kymera Therapeutics investors | BlackRock, Atlas Venture, Bessemer Venture Partners, Wellington Management, Redmile Group, Lilly Ventures, Pfizer Venture Investments, Amgen Ventures, Aju IB Investment, Hatteras Venture Partners, Rock Springs Capital, Biotechnology Value Fund, Sanofi-Genzyme BioVentures, Bain Capital Life Sciences, 6 Dimensions Capital, Janus Henderson Investors, MRL Ventures Fund |
Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Kymera Therapeutics Cybersecurity Score
Kymera Therapeutics Online and Social Media Presence
2.15k Twitter followers
Kymera Therapeutics has 2.15k Twitter Followers. The number of followers has increased 4.3% month over month and increased 6.3% quarter over quarter
Kymera Therapeutics's Trends
Twitter Engagement Stats for @KymeraTx
505
Tweets
137
Following
2.1k
Followers
9
Tweets last 30 days
12.3
Avg. likes per Tweet
100%
Tweets with engagement
Kymera Therapeutics News and Updates
July 29, 2021
Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice Pr…
July 12, 2021
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation
July 06, 2021
Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public…
July 01, 2021
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public…
June 28, 2021
Kymera Therapeutics Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public o…
June 28, 2021
Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Kymera Therapeutics Blogs
July 12, 2021
13th Annual T-Cell Lymphoma Forum, July 8-10, 2021
Poster: Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL
The post 13th Annual T-Cell Lymphoma Forum, July 8-10, 2021 appeared first on Kymera Therapeutics.
July 06, 2021
The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation
The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis - the promise of these advantages has ma…
June 20, 2021
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021
Presentation: KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
The post 16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021 appe…
June 09, 2021
Marking Kymera’s 5-Year Anniversary Video
The post Marking Kymera’s 5-Year Anniversary Video appeared first on Kymera Therapeutics.
June 07, 2021
Marking Kymera’s 5-Year Anniversary
Kymera was founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of a powerful new class of medicines based on targeted protein degradation (TPD). As we celebrate Kymera’s five-year anniversary, I look back and reflect on the inspiratio…
May 26, 2021
Ligase Targeting Drug Development Summit, May 25 – 27, 2021
Poster Presentation: Drugging Tissue-Restricted E3 Ligases
The post Ligase Targeting Drug Development Summit, May 25 – 27, 2021 appeared first on Kymera Therapeutics.
Kymera Therapeutics Frequently Asked Questions
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2017.
Who are Kymera Therapeutics key executives?
Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics has 105 employees.
Who are Kymera Therapeutics competitors?
Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Synspira.
Where is Kymera Therapeutics headquarters?
Kymera Therapeutics headquarters is located at 200 Arsenal Yards Blvd #230, Watertown.
Where are Kymera Therapeutics offices?
Kymera Therapeutics has an office in Watertown.
How many offices does Kymera Therapeutics have?
Kymera Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies